Lantheus acquires global rights to Life Molecular's GRPR-targeting radiotheranostic pair for $35M upfront

Lantheus Holdings, Inc.

Upfront payment $35M plus regulatory milestone payments and royalties.
Pair includes 177Lu-DOTA-RM2 (therapeutic) and 68Ga-DOTA-RM2 (diagnostic) targeting GRPR in prostate, breast, and other cancers.
Lantheus plans Phase 1/2a study with 177Lu-DOTA-RM2 in prostate cancer in 2025; 68Ga-DOTA-RM2 as companion diagnostic.
Strengthens Lantheus' prostate cancer portfolio and expands pipeline to include breast cancer.
Life Molecular will complete ongoing Phase 1/2a dose escalation study in collaboration with Lantheus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.